DK163107B - Fremgangsmaade til fremstilling af et koncentrat af antihaemofilisk faktor med hoej renhed - Google Patents
Fremgangsmaade til fremstilling af et koncentrat af antihaemofilisk faktor med hoej renhed Download PDFInfo
- Publication number
- DK163107B DK163107B DK450785A DK450785A DK163107B DK 163107 B DK163107 B DK 163107B DK 450785 A DK450785 A DK 450785A DK 450785 A DK450785 A DK 450785A DK 163107 B DK163107 B DK 163107B
- Authority
- DK
- Denmark
- Prior art keywords
- approx
- weight
- precipitate
- solution
- polyethylene glycol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 239000012141 concentrate Substances 0.000 title claims abstract description 20
- 230000000603 anti-haemophilic effect Effects 0.000 title claims description 23
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 92
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 81
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 81
- 239000004471 Glycine Substances 0.000 claims abstract description 54
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 52
- 210000002381 plasma Anatomy 0.000 claims abstract description 45
- 230000008569 process Effects 0.000 claims abstract description 33
- 239000000725 suspension Substances 0.000 claims abstract description 32
- 239000011780 sodium chloride Substances 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract description 22
- 102100026735 Coagulation factor VIII Human genes 0.000 claims abstract description 8
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims abstract description 8
- 239000002244 precipitate Substances 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 39
- 229920000669 heparin Polymers 0.000 claims description 37
- 229960002897 heparin Drugs 0.000 claims description 31
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 108010049003 Fibrinogen Proteins 0.000 claims description 19
- 102000008946 Fibrinogen Human genes 0.000 claims description 19
- 229940012952 fibrinogen Drugs 0.000 claims description 19
- 239000007858 starting material Substances 0.000 claims description 18
- 102000004506 Blood Proteins Human genes 0.000 claims description 7
- 108010017384 Blood Proteins Proteins 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 208000037319 Hepatitis infectious Diseases 0.000 claims 3
- 230000006920 protein precipitation Effects 0.000 claims 1
- 239000011369 resultant mixture Substances 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000001556 precipitation Methods 0.000 abstract description 17
- 230000006872 improvement Effects 0.000 abstract description 8
- 239000006185 dispersion Substances 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 85
- 239000000047 product Substances 0.000 description 34
- 229960000301 factor viii Drugs 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 108010054218 Factor VIII Proteins 0.000 description 22
- 102000001690 Factor VIII Human genes 0.000 description 22
- 235000008504 concentrate Nutrition 0.000 description 17
- 239000000872 buffer Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 229940024545 aluminum hydroxide Drugs 0.000 description 10
- 238000000108 ultra-filtration Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000011146 sterile filtration Methods 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002947 procoagulating effect Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 102100037362 Fibronectin Human genes 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 4
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- YBHYYFYQHRADCQ-UHFFFAOYSA-N 2-aminoacetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NCC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O YBHYYFYQHRADCQ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- -1 glycine-polyethylene Chemical group 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MWLUPTBKTSQFNA-UHFFFAOYSA-N 2-aminoacetic acid;ethanol Chemical compound CCO.NCC(O)=O MWLUPTBKTSQFNA-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CBQJSKKFNMDLON-JTQLQIEISA-N N-acetyl-L-phenylalanine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-N 0.000 description 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000272171 Scolopacidae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- JNKFBZKIIRHPNY-UHFFFAOYSA-M [Na+].[Cl-].NCC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O Chemical compound [Na+].[Cl-].NCC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O JNKFBZKIIRHPNY-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940079718 acetyltryptophanate Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000012760 heat stabilizer Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- RLEFZEWKMQQZOA-UHFFFAOYSA-M potassium;octanoate Chemical compound [K+].CCCCCCCC([O-])=O RLEFZEWKMQQZOA-UHFFFAOYSA-M 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ZFEKVFJKFDZSHE-UHFFFAOYSA-M sodium;2-aminoacetic acid;chloride Chemical compound [Na+].[Cl-].NCC(O)=O ZFEKVFJKFDZSHE-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/658,081 US4543210A (en) | 1984-10-04 | 1984-10-04 | Process for producing a high purity antihemophilic factor concentrate |
| US65808184 | 1984-10-04 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK450785D0 DK450785D0 (da) | 1985-10-03 |
| DK450785A DK450785A (da) | 1986-04-05 |
| DK163107B true DK163107B (da) | 1992-01-20 |
Family
ID=24639818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK450785A DK163107B (da) | 1984-10-04 | 1985-10-03 | Fremgangsmaade til fremstilling af et koncentrat af antihaemofilisk faktor med hoej renhed |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4543210A (de) |
| EP (1) | EP0176926B1 (de) |
| JP (1) | JPH0676337B2 (de) |
| AT (1) | ATE44236T1 (de) |
| CA (1) | CA1243950A (de) |
| DE (1) | DE3571201D1 (de) |
| DK (1) | DK163107B (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650858A (en) * | 1983-03-21 | 1987-03-17 | Nordisk Gentofte A/S | Concentrate of the antihemophilic factor VIII and a process for producing it |
| SE8501050D0 (sv) * | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
| CA1293941C (en) * | 1985-11-08 | 1992-01-07 | Maria Erlinda Co-Sarno | Method for preparing antihemophilic factor (ahf) by cold precipitation and for improving solubility of recovered ahf product |
| EP0238701B1 (de) * | 1986-03-27 | 1992-03-18 | Octapharma AG | Verfahren zur Herstellung eines hochgereinigten Antihämophilie-Faktors |
| AT391808B (de) * | 1986-11-03 | 1990-12-10 | Immuno Ag | Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion |
| US5177191A (en) * | 1987-12-21 | 1993-01-05 | Miles, Inc. | Gel filtration of factor VIII |
| EP0321835B1 (de) * | 1987-12-21 | 1994-09-28 | Miles Inc. | Faktor VIII- Gelfiltration |
| FR2632309B1 (fr) * | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
| DE3904354A1 (de) * | 1989-02-14 | 1990-08-16 | Behringwerke Ag | Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung |
| DE69002033T2 (de) * | 1989-05-24 | 1993-09-30 | Miles Inc | Gelfiltration von wärmebehandeltem Faktor VIII. |
| USH1509H (en) * | 1989-06-09 | 1995-12-05 | Eran; Harutyun | Heparin enhanced process for separating antihemophilic factor (Factor VIII) and fibronectin from cryoprecipitate |
| FR2651437A1 (fr) * | 1989-09-05 | 1991-03-08 | Lille Transfusion Sanguine | Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total. |
| DK162233C (da) * | 1989-11-09 | 1992-03-16 | Novo Nordisk As | Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii |
| IT1248723B (it) * | 1990-06-12 | 1995-01-26 | Scalvo S P A | Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo |
| FR2664165B1 (fr) * | 1990-07-03 | 1992-10-16 | Lille Transfusion Sanguine | Composition pour stabiliser le plasma sanguin en cours de pasteurisation. |
| US5525519A (en) * | 1992-01-07 | 1996-06-11 | Middlesex Sciences, Inc. | Method for isolating biomolecules from a biological sample with linear polymers |
| DE4202667C1 (de) * | 1992-01-29 | 1993-05-13 | Behringwerke Ag, 3550 Marburg, De | |
| US5288853A (en) * | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
| US5659017A (en) * | 1995-11-07 | 1997-08-19 | Alpha Therapeutic Corporation | Anion exchange process for the purification of Factor VIII |
| DK2130554T3 (da) | 1999-02-22 | 2012-12-03 | Univ Connecticut | Albuminfrie faktor VIII-præparater |
| CA2394797A1 (en) * | 1999-12-20 | 2001-06-28 | Tsuyoshi Takahashi | Process for producing virus-free plasma protein composition by porous membrane treatment, virus-free plasma protein composition and method of removing viruses |
| AU2009313325B2 (en) * | 2008-11-07 | 2014-05-01 | Takeda Pharmaceutical Company Limited | Factor VIII formulations |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US29698A (en) * | 1860-08-21 | Improvement in harvesters | ||
| NL286954A (de) * | 1962-01-03 | |||
| US3652530A (en) * | 1967-08-28 | 1972-03-28 | American Nat Red Cross | Antihemophilic factor prepared from blood plasma using polyethylene glycol |
| US3631018A (en) * | 1970-05-01 | 1971-12-28 | Baxter Laboratories Inc | Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate |
| US3682881A (en) * | 1970-10-02 | 1972-08-08 | Baxter Laboratories Inc | Fractionation of plasma using glycine and polyethylene glycol |
| US3803115A (en) | 1972-05-17 | 1974-04-09 | Baxter Laboratories Inc | Stabilization of ahf using heparin |
| US4188318A (en) * | 1975-06-16 | 1980-02-12 | Edward Shanbrom | Simplified method for preparation of high yield, high purity Factor VIII concentrate |
| US4069216A (en) * | 1975-06-16 | 1978-01-17 | Edward Shanbrom, Inc. | Simplified methods for preparation of very high purity Factor VIII concentrate |
| US4104266A (en) * | 1977-04-14 | 1978-08-01 | American National Red Cross | Method for preparation of antihemophilic factor |
| CA1074698A (en) * | 1977-12-19 | 1980-04-01 | Gail A. Rock | Method of collecting anti-hemophilic factor viii from blood and blood plasma |
| US4170639A (en) * | 1978-07-10 | 1979-10-09 | Warner-Lambert Company | Antihemophilic factor concentrate and its production |
| US4210580A (en) * | 1979-06-19 | 1980-07-01 | David Amrani | Process for separation and isolation of AHF and fibronectin from blood plasma |
| FR2460305A2 (fr) * | 1979-06-29 | 1981-01-23 | Merieux Inst | Procede de preparation d'un concentre de facteur viii |
| SE448945B (sv) * | 1979-12-20 | 1987-03-30 | Blombaeck E G B | Forfarande for rening och /eller koncentrering av faktor viii-komplexet |
| US4289691A (en) * | 1980-01-18 | 1981-09-15 | The Canadian Red Cross Society | Method of obtaining intermediate purity factor VIII |
| US4386068A (en) * | 1980-02-26 | 1983-05-31 | Cutter Laboratories, Inc. | Antihemophilic factor concentrate and method for preparation |
| US4294826A (en) * | 1980-05-07 | 1981-10-13 | Armour Pharmaceutical Company | Process for the preparation of highly purified antihemophilic factor |
| AT369263B (de) * | 1980-08-27 | 1982-12-27 | Immuno Ag | Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates |
| US4359463A (en) * | 1980-11-26 | 1982-11-16 | Rock Gail A | Stabilization of Factor VIII activity in whole blood or blood plasma |
| US4435318A (en) * | 1981-05-22 | 1984-03-06 | Ionics, Incorporated | Electrodialysis preparation of purified AHF concentrate |
| CA1178887A (en) * | 1981-10-01 | 1984-12-04 | Gail A. Rock | Factor viii concentrates prepared from heparinized plasma by the application of a cold precipitation technique |
| US4495175A (en) * | 1982-08-05 | 1985-01-22 | University Of Rochester | Preparation of highly purified human antihemophilic factor |
| US4486410A (en) * | 1984-02-09 | 1984-12-04 | Armour Pharmaceutical Company | Heat defibrinogenation of AHF preparation |
-
1984
- 1984-10-04 US US06/658,081 patent/US4543210A/en not_active Expired - Lifetime
-
1985
- 1985-06-28 CA CA000486007A patent/CA1243950A/en not_active Expired
- 1985-07-31 JP JP60167835A patent/JPH0676337B2/ja not_active Expired - Lifetime
- 1985-09-24 AT AT85112070T patent/ATE44236T1/de not_active IP Right Cessation
- 1985-09-24 DE DE8585112070T patent/DE3571201D1/de not_active Expired
- 1985-09-24 EP EP85112070A patent/EP0176926B1/de not_active Expired
- 1985-10-03 DK DK450785A patent/DK163107B/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0176926B1 (de) | 1989-06-28 |
| DK450785D0 (da) | 1985-10-03 |
| JPH0676337B2 (ja) | 1994-09-28 |
| ATE44236T1 (de) | 1989-07-15 |
| EP0176926A3 (en) | 1987-10-28 |
| US4543210A (en) | 1985-09-24 |
| JPS6187626A (ja) | 1986-05-06 |
| DK450785A (da) | 1986-04-05 |
| CA1243950A (en) | 1988-11-01 |
| EP0176926A2 (de) | 1986-04-09 |
| DE3571201D1 (en) | 1989-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK163107B (da) | Fremgangsmaade til fremstilling af et koncentrat af antihaemofilisk faktor med hoej renhed | |
| EP0037078B1 (de) | Verfahren zur Wärmebehandlung einer wässrigen Lösung, die den menschlichen Blutkoagulationsfaktor XIII enthält | |
| US5099003A (en) | Method of preparing a sterile plasma-protein solution containing fibrinogen and factor xiii | |
| US5151499A (en) | Production method for protein-containing composition | |
| DK156698B (da) | Fremgangsmaade til pasteurisering af et materiale indeholdende et termisk foelsomt, terapeutisk aktivtprotein valgt blandt alfa-l-antitrypsin, antithrombin-iii, praekallikrein, antihaemofil faktor (faktorviii) og fibronectin | |
| DK174066B1 (da) | Fremgangsmåde til fremstilling af et faktor VIII-præparat | |
| JPH0543688B2 (de) | ||
| AU549584B2 (en) | Heat stabilization of plasma proteins | |
| EP0252392B1 (de) | Virale Inaktivierung und Reinigung von aktiven Proteinen | |
| US4814435A (en) | Method of producing a factor VIII (AHF) containing fraction | |
| USH1509H (en) | Heparin enhanced process for separating antihemophilic factor (Factor VIII) and fibronectin from cryoprecipitate | |
| JPH0348888B2 (de) | ||
| DK167900B1 (da) | Middel til behandling og forebyggelse af haemostatiske forstyrrelser indeholdende vaevsprotein pp4 | |
| EP0011739B1 (de) | Verfahren zur Gewinnung von Blutkoagulations-Faktor XIII aus menschlicher Plazenta | |
| WO2007046631A1 (en) | Method for manufacturing high purified factor ix | |
| US5043428A (en) | Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production | |
| JPS61189228A (ja) | 血液凝固第８因子製剤の製法 | |
| JPS597695B2 (ja) | 免疫制御作用を有するペプタイド製剤 | |
| JPH01305036A (ja) | 血漿蛋白成分の加熱処理方法および血漿蛋白成分製剤 | |
| Ng et al. | Preparation of high purity factor VIII concentrates | |
| JPS62195331A (ja) | 血液凝固第８因子製剤の製法 | |
| JP2678193B2 (ja) | ヒト血漿由来血液凝固第ｘ▲ｉｉｉ▼因子の製造方法 | |
| DK175644B1 (da) | Fremgangsmåde til stabilisering af biologiske og farmaceutiske midler under inaktivering af virale og bakterielle kontaminanter | |
| EP0076870A1 (de) | Verfahren zur Herstellung von hochgereinigtem Antihaemophiliefaktor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PRF | Application refused |